VC firms, biotechs push back on drug pricing bill that would render small molecule drugs 'uninvestable' As COVID market narrows, SaNOtize moves to carve a new one: over-the-counter prevention China's Rona raises stake in the siRNA game by buying platform, 4 preclinical liver drugs from Sanofi Sponsored: Unlocking the power of AI-driven pathology in drug development: An Interview with Bristol Myers Squibb 7 months after announcing a pivot to drug discovery, Zymergen is acquired by Ginkgo Pfizer, BMS vet hits Replay with $55M seed financing, 'Big DNA' ambitions Beyond skin supplements: collagen could be the next target for cancer therapies From CVS to Google, here are 20 healthcare executives to watch Idorsia taps Olympic gold medalist Lindsey Vonn as its latest celebrity spokeswoman Enhertu's groundbreaking HER2-low breast cancer nod could come this year as AZ, Daiichi seek ambitious approval How Amazon's One Medical deal could boost its healthcare ambitions and heat up competition Philips predicts sleep machine sales to recover by 2025 as ventilator recall rages on Featured Story | By Annalee Armstrong Some of the leading biotech investment firms say the senate’s proposed drug pricing bill will render the pursuit of small molecule drugs “uninvestable,” especially new therapies for diseases of aging, including Alzheimer’s disease, blindness, amyotrophic lateral sclerosis and more. read more |
| |
|---|
|
Top Stories By Max Bayer There are currently zero authorized or approved preventative COVID therapies in the U.S. but Canadian biotech SaNOtize wants to change that, charting plans to move a nasal spray into a phase 3 study as soon as October. read more By James Waldron After raising $33 million back in April, the Shanghai-based biotech is using some of that money to acquire a small interference RNA platform and four preclinical candidates from Sanofi. read more Sponsored by: PathAI Learn how Bristol Myers Squibb is unlocking new insights in translational research and development by transforming pathology with artificial intelligence. read more By James Waldron Zymergen aimed to leave its well-publicized woes behind through a new-year transformation into a biotech. Now the company has been picked up by Ginkgo Bioworks, which will look for “strategic alternatives” for the new drug discovery business once the sale is complete. read more By Gabrielle Masson New biotech Replay—led by former Pfizer and Bristol Myers Squibb executive Adrian Woolfson, Ph.D.—has unveiled with a $55 million seed financing to reprogram biology and author next generation genomic products. read more By James Waldron Collagen supplements may be a regular fixture on the shelves of your local vitamin shop, but researchers at the University of Texas have suggested that this most abundant protein in the body may have a new use: to fight cancer. read more By Anastassia Gliadkovskaya,Robert King,Susan Kreimer,Heather Landi,Paige Minemyer,Dave Muoio,Jacqueline Renfrow Healthcare is complicated, and few people know that better than the executives leading the industry. Meet the 20 we're highlighting here, and let us know on Twitter at @FierceHealth the executives you're watching. read more By Natalie Missakian World champion skier and Olympic gold medalist Lindsey Vonn was a good sleeper until a serious knee injury in 2013 and subsequent surgery set her on a path of sleepless nights that lasted nearly a decade. read more By Angus Liu After winning a standing ovation at the recent ASCO event, Enhertu’s HER2-low breast cancer data are now getting the VIP treatment at the FDA. And AstraZeneca and Daiichi Sankyo are targeting an ambitiously broad patient population. read more By Heather Landi As Amazon has built its business with a laser focus on the consumer, the company's bigger push into healthcare raises the stakes for other players to take a consumer-centric approach, industry experts say. Businesses like Amazon with a national customer base have a unique opportunity to expand their share of wallet with loyal customers. read more By Andrea Park While declines in recent quarters have primarily been attributed to its vast ventilator recall effort and ongoing supply chain issues, this time around Philips linked its sales slump in large part to COVID-19 lockdowns in China. read more Resources Sponsored by: NetApp Could cloud be the cure for your EHR headaches? See our infographic on how moving to the cloud can slash financial and administrative burdens. Sponsored by: Lumanity Join us, as we explore the commercial readiness challenges and practical realities of driving a successful launch in the cell and gene therapy space. Sponsored by: Triangle Insights Group, LLC Discover how the new partnership between TrialCard and Triangle Insights Group can help you bridge the critical gap between strategy and execution, ensuring commercialization success of your product or therapy. Sponsored by: Nexelis Discover Nexelis’ first-hand perspective on how to develop innovative, agile solutions in vaccine efficacy testing in this exclusive e-book. Sponsored by: Cognizant Explore how Cognizant SIP helped Roche streamline its global feasibility process. Sponsored by: Blue Matter Consulting This e-book covers the 12 most common pitfalls for companies entering European markets for the first time, offering guidance to help growing companies avoid them and succeed. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Fierce Biotech Cell & Gene Therapy Forum October 19, 2022 | Free Virtual Event Fierce Pharma Meeting Professionals Summit November 2-3, 2022 | Atlantic City, NJ | 